Management of bleeding with uremia and liver disease

Current Opinion in Hematology

Volumn 6, Issue 5, 1999, Pages 329-333

  Deloughery, T G ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR; DESMOPRESSIN; ERYTHROPOIETIN; ESTROGEN; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROGESTERONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE CONCENTRATE; THROMBOPOIETIN; WARFARIN;

BLEEDING; CRYOPRECIPITATE; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; GASTROINTESTINAL HEMORRHAGE; GRAFT OCCLUSION; HEMATOCRIT; HEMODIALYSIS; HUMAN; LIVER DISEASE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; UREMIA;

HEMORRHAGE; HUMAN; LIVER DISEASES; UREMIA;

EID: 0033302948     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199909000-00010     Document Type: Review

References (32)

1. Uremic bleeding: Pathogenesis and therapy
2. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article
3. Bleeding and thrombosis in chronic uremia
4. Moderate doses of aspirin and risk of bleeding in renal failure
5. Uremia as a cause of bleeding
6. Hemostatic drugs
7. Variability in response to cryoprecipitate treatment for hemostatic defects in uremia
8. Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia
9. Estrogen-progesterone therapy for bleeding gastrointestinal telangiectasias in chronic renal failure: An uncontrolled trial
10. Beneficial effect of low-dose transdermal estrogen on bleeding time and clinical bleeding in uremia
11. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin
12. Effects of epoetin alfa on hemostasis in chronic renal failure
13. Pooling of platelets in the spleen: Role in the pathogenesis of 'hypersplenic' thrombocytopenia
14. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation
15. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?
16. Competitions between fibrinogen with its degradation products for interactions with the platelet-fibrinogen receptor
17. Platelets and thrombolytic therapy
18. Bleeding time does not predict gastrointestinal bleeding in patients with cirrhosis: Coagulation abnormalities in liver cirrhosis
19. Association between high values of D-dimer and tissue-plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients
20. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage
21. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis: Coagulation abnormalities in liver cirrhosis: The CALC Group
22. Fibrinolysis at rest and after exercise in hepatic cirrhosis
23. Biliary tract surgery and cirrhosis: A critical combination
24. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors
25. Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassaemia
26. Prothrombin time in liver failure: Time, ratio, activity percentage, or international normalized ratio
27. Assessment of the validity of the INR system for patients with liver impairment
28. Effect of plasma transfusions on the prothrombin time and clotting factors in liver disease
29. Other coagulation factor deficiencies
30. Hemostatic disorders in liver disease
31. Antifibrinolytic agents
32. Recombinant factor Vlla corrects prothrombin time in cirrhotic patients: A preliminary study